In a significant development, the FDA has recently lifted its hold on AIM Immunotech. Resulting in a remarkable 25% surge…
Browsing: Biotechnology
In a recent phase 1/2 clinical trial, AIM ImmunoTech has announced encouraging results from its study involving ovarian cancer patients.…
If you’re an investor seeking healthcare stocks with promising returns, PainReform and T2 Biosystems should be on your radar. Over…
AIM ImmunoTech Inc. (AIM) has achieved a significant breakthrough in ovarian cancer treatment. As evidenced by the positive data from…
AIM ImmunoTech Inc. has recently embarked on a promising collaboration with the U.S. National Institute of Allergy and Infectious Diseases…
MorphoSys, the German biopharmaceutical company, has recently made a strategic decision to shift its focus from pre-clinical research to clinical-stage…